RBF Capital’s Standard BioTools LAB Stock Holding History

RBF Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,572	Closed	-$178K	–	606
2024 Q2	$178K	Sell	100,572 -341,000	-77%	-$834K	0.01%	527
2024 Q1	$1.2M	Buy	+441,572	New	+$1.07M	0.07%	268

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital's LAB Position: Q3 2024 in Review

RBF Capital sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 100,572 shares — an estimated $178K sold.

RBF Capital first reported a position in LAB in Q1 2024 and held it in 2 quarters. The position peaked at $1.2M in Q1 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

RBF Capital reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
RBF Capital sold 100,572 Standard BioTools shares in Q3 2024, an estimated $178K.
RBF Capital first reported a position in Standard BioTools in Q1 2024 and held it in 2 quarters.
RBF Capital's Standard BioTools position peaked at $1.2M in Q1 2024.
141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on RBF Capital's 13F filing for Q3 2024, filed 14 Nov 2024.